Vous êtes sur la page 1sur 2

Tamsulosin P medicine

A QUICK REFERENCE GUIDE

Tamsulosin is indicated for the treatment of functional symptoms (i.e. urinary retention) of benign prostatic
hyperplasia (prostate enlargement); commonly referred to as BPH. Tamsulosin is an alpha1-adrenoceptor antagonist
(alpha-blocker) that relaxes the muscles in the prostate gland and urethra thereby increasing the urinary flow-rate and
an improvement in obstructive symptoms.
See the NICE guidance - Lower urinary tract symptoms in men; management (CG97) for information on lower urinary
tract symptoms in men.
Supply criteria
Male patient: aged between 45 and 75 years of age
Symptoms of BPH present for a minimum of three months
A two week supply of tamsulosin can be supplied initially
If there has been an improvement in urinary symptoms within the initial two
weeks, a further supply of four weeks can be made
After 6 weeks, a further supply can be made only where the patient confirms
that the doctor has carried out a clinical assessment and agreed further
supplies are appropriate

Precautions for use


If patient has planned surgery for glaucoma or cataract
Use in caution with strong and moderate CYP3A4 inhibitors (e.g.
ketoconazole and erythromycin)
Enhanced hypotensive effects if taken with antihypertensives

Counselling points
One capsule to be taken after the same meal each day
Modified-release preparations should be swallowed whole: not crushed or chewed
Patients should see their doctor within six weeks of starting treatment
Patients should see their doctor every 12 months for a clinical review
Patients should be advised that if they experience any dizziness or weakness they should sit or lie down until the
symptoms have gone
Drowsiness or dizziness may affect performance of skilled tasks (e.g. driving)

Further information:
Summary of Product Characteristics (Electronic Medicines Compendium): https://www.medicines.org.uk/emc/
BNF: www.bnf.org/
NHS Choices: www.nhs.uk/pages/home.aspx
NICE guidance: Lower urinary tract symptoms in men: management (CG97)
Members can contact RPS Professional support:
Online: www.rpharms.com/enquiry Phone: 0845 257 2570 Email: support@rpharms.com
Issued April 2016
Copyright Royal Pharmaceutical Society 2016

Tamsulosin - Contraindications (and other referral criteria)


Interactions:

Patient characteristics:

Other contraindications:

Strong CYP3A4 inhibitors


(e.g. ketoconazole,
erythromycin)

Under 45 or over 75 years of


age

Severe hepatic insufficiency

Verapamil

Where patient has surgery


for glaucoma or cataract
scheduled

Diclofenac
Warfarin

Warning:

Symptoms:

Enhanced hypotensive
effects with other alpha1adrenoceptor antagonists
i.e

Symptoms for less than


three months

- doxazosin

Referral

Dysuria
Haematuria
Cloudy urine

- indoramin

Fever (possible undiagnosed


UTI)

- prazosin
- terazosin

History of:

Hypersensitivity to:

Referral criteria:

Postural or orthostatic
hypotension

Tamsulosin

Stop treatment if symptoms


have not improved (or are
getting worse) after the
initial 14 day treatment

Heart, kidney or liver


disease
Diabetes - if uncontrolled
Urinary incontinence
Previous prostate surgery
Blurred/cloudy vision
(undiagnosed)

Any other ingredient in the


preparation

Patients should see their


doctor within 6 weeks of
starting OTC tamsulosin
and confirm continued
treatment is appropriate
Patients must see their
doctor at least every 12
months to enable further
OTC supply (after the initial
six weeks of treatment)

The information in this guide is based on the Summary of Product Characteristics of OTC tamsulosin. The guide is
intended as a quick reference and you should interpret all information and advice in the light of your own professional
knowledge.

Issued April 2016


Copyright Royal Pharmaceutical Society 2016

Vous aimerez peut-être aussi